Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 4th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 4th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

September 7th 2015

CVS: Taking Tobacco From Stores Prompted Quit Attempts; Sales of Cigarettes Dropped

Mary K. Caffrey

Data in study show removal of tobacco from stores led to surge in purchase of nicotine patches.

September 7th 2015

Keytruda Gains NICE Approval While Kadcyla Fails

Surabhi Dangi-Garimella, PhD

Cancer drug cost troubles in the UK prompt NHS to slash its list of approved-for-use oncology products.

September 7th 2015

Dr Amy Davidoff Examines Factors Influencing Patient Treatment Decisions in Cancer Care

For individuals who have not made the sort of risk-averse decisions in their lives that lead to better jobs and wealth accumulation, making treatment decisions after a cancer diagnosis can be very difficult, said Amy Davidoff, PhD, MS, senior research scientist in public health at the Yale School of Public Health

September 7th 2015

Watch and Wait Feasible in Nearly 70% of Men With Prostate Cancer, Study Suggests

Surabhi Dangi-Garimella, PhD

Urologists analyzing data from prostate cancer patients suggest wait and watch in well-informed low-risk prostate cancer patients.

September 6th 2015

Dr Robert Dubois Outlines the Creation, Utilization of Clinical Pathways

A survey of groups using and developing clinical pathways revealed 7 distinct themes that highlight how these pathways are created and used, and the challenges and barriers to creating new pathways, explained Robert Dubois, MD, PhD, chief science officer and executive vice president of the National Pharmaceutical Council.

September 4th 2015

Integrating Genomics into Pediatric Cancer Care

Surabhi Dangi-Garimella, PhD

Study provides proof that a child's genetic makeup can provide actionable information to alter cancer treatment regimens.

September 3rd 2015

Long-Anticipated Biosimilar From Novartis Launched, but at What Price?

Surabhi Dangi-Garimella, PhD

Novartis has announced that Zarxio will be available at 15% of the cost of its reference product Neupogen.

September 3rd 2015

Prophylactic Breast Surgery on the Rise in Men With Breast Cancer

Surabhi Dangi-Garimella, PhD

Men are opting for preventive breast surgery when diagnosed with unilateral invasive disease, a study published in JAMA Surgery has found.

September 2nd 2015

Telehealth Intervention Can Overcome Barriers to Colorectal Screening

Surabhi Dangi-Garimella, PhD

Personalized telephone counseling and tailored educational materials can improve colonoscopy rates among at-risk family members of patients with colorectal cancer.

September 2nd 2015

Rolapitant Gains FDA Approval for CINV

AJMC Staff

Rolapitant was approved to prevent delayed phase chemotherapy-induced nausea and vomiting in adult patients.

September 1st 2015

ASCO Publishes Policy Update on Genomic Testing for Cancer Susceptibility

Surabhi Dangi-Garimella, PhD

The Cancer Prevention and Ethics Committees of the American Society of Clinical Oncology have made several recommendations that address genetic and genomic testing policies for cancer risk assessment.

September 1st 2015

Mary Lou Smith on Ensuring Patients' Voices Are Heard

Sometimes patients are so concerned with being good patients that they simply agree to what the clinician has said without fully understanding, and it's important to ask questions and ensure their voices are heard, said Mary Lou Smith, MBA, co-founder of the Research Advocacy Network.

September 1st 2015

Elotuzumab Accepted for Priority Review by FDA for Previously-Treated Patients With Multiple Myeloma

Surabhi Dangi-Garimella, PhD

The submission by BMS includes results from the ELOQUENT-2 trial that were recently published in the New England Journal of Medicine.

August 31st 2015

Gene Signature Could Predict Development of Pancreatic Cancer, Allow Personalized Treatment

Surabhi Dangi-Garimella, PhD

A novel microRNA gene signature could guide earlier intervention in pancreatic cancer.

August 31st 2015

ASCO Updates Guidelines for Advanced Lung Cancer

Surabhi Dangi-Garimella, PhD

An expert panel of ASCO developed recommendations for advanced lung cancer treatment after reviewing published literature.

August 31st 2015

New 340B Draft Guidance May Increase Bureaucracy

Surabhi Dangi-Garimella, PhD

The new guidance released by HRSA proposes to improve oversight over the drug pricing program.

August 30th 2015

Pharmacy Cost Trends Expected to Continue in the Double Digits

AJMC Staff

Pharmacy cost trends are expected to increase 10% up from 6.3% the year before, with specialty pharmacy trends experiencing the largest increases, according to a survey from Aon Health.

August 28th 2015

Protein Biomarker Can Predict Response to FOLFIRINOX in Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

The study published in JNCI has identified CES2 expression as a predictor of response to FOLFIRINOX.

August 28th 2015

Jennifer Malin, MD, Explains Payer Role In Changing Cancer Care

While the shift to cancer becoming more of a chronic disease does not have a huge change on the approach of the payer, there are some new challenges to address, said Jennifer Malin, MD, medical director for oncology at Anthem.

August 27th 2015

Childhood Cancer Increases Risk of Recurrent Stroke

Surabhi Dangi-Garimella, PhD

Published in the journal Neurology, the study identified childhood cancer, along with hypertension and age, as a risk factor for recurrent stroke.

August 27th 2015

A New Decision Support Tool for Surgical Oncology Launched

AJMC Staff

A pathways company has followed up its medical and radiation oncology clinical decision tools with a new surgical oncology platform.

August 26th 2015

As Date for First Biosimilar to Hit the Market Draws Close, Reimbursement Remains Fuzzy

Surabhi Dangi-Garimella, PhD

August 26th 2015

Do Survivorship Care Plans Improve PROs Among Cancer Patients?

Surabhi Dangi-Garimella, PhD

An article published in the Journal of Clinical Oncology finds that survivorship care plans may not greatly improve patient satisfaction with their care.

August 25th 2015

Colorectal Cancer Screening Gets Special Look in AJMC Papers

The deadly nature of colorectal cancer merited attention in the Affordable Care Act, which called for eliminating cost-sharing for screening to prevent deaths. The future of colorectal screening, its cost-effectiveness, and a possible way to limit unneeded tests are the topic of a recent series of papers in The American Journal of Managed Care.

August 25th 2015

Study Shows Promise for EHR-Based Algorithm in Reducing Cancer Diagnostic Delays

Surabhi Dangi-Garimella, PhD

A trigger built in patient EHRs can avoid follow-up delays in those at risk for developing certain types of cancers, a JCO study shows.

August 25th 2015

A Payer-Provider Collaboration to Add Value to Oncology Care

Surabhi Dangi-Garimella, PhD

Aetna and the University of Chicago Medicine kicked off a value-based oncology medical home model in July this year in an effort to transition from fee-for-service to value-based care.

August 24th 2015

Another Cancer Drug Pricing Tool, This Time From NCCN

Surabhi Dangi-Garimella, PhD

The National Comprehensive Cancer Network has announced the development of another "price" calculator that will help stakeholders assess the relative "value" of available options.

August 21st 2015

New Study Unravels Link Between Obesity and Breast Cancer

Surabhi Dangi-Garimella, PhD

The study published in Science Translational Medicine found that tissue stiffening in the breasts of obese women can drive the development of malignant disease.

August 20th 2015

Dr Veena Shankaran Encourages Patient-Physician Communication of Care Costs

There are many cost-related pieces in the grand picture of care that are devastating to families and patients, including copayments, hospital visit bills, transportation fees, and drug prices.

August 20th 2015

Phase 2 Basket Trial Results Claim Success in BRaf V600-Mutated Cancers

Surabhi Dangi-Garimella, PhD

Conducted by researchers at the Memorial Sloan Kettering Cancer Center, phase 2 results from a basket trial evaluated the efficacy of vemurafenib on nonmelanoma BRaf V600-mutated cancers in 122 patients across 23 global centers.

...

123 124 125 126 127 128 129 130 131

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions